New Insulin Toujeo: Now Approved and Available Soon!

Roni Shye
Roni Shye, PharmD BCGP BCACP, is a licensed pharmacist in the states of Florida, Ohio, and Pennsylvania.
Posted on

On February 25, 2015, the FDA approved Toujeo—a long-acting insulin indicated to improve sugar control in adults with type 1 and type 2 diabetes.

When will Toujeo be available?

According to the manufacturer, Sanofi-Aventis, Toujeo will be available at the beginning of the second quarter in 2015.

What is long-acting insulin?

Long-acting insulin can also be referred to as basal insulin. Long-acting insulin lowers blood sugar levels slowly and evenly for up to 24 hours. This means that Toujeo manages blood sugar between meals and at nighttime.

Are there other long-acting insulins available?

Yes. These medications are also examples of long-acting insulin: Lantus (100 units/mL), which comes in a vial or SoloStar pen, and Levemir (100 units/mL), also which comes in a vial or FlexTouch pen.

Is Toujeo similar to any of the other long-acting insulins?

Yes. Toujeo has the same active ingredient, insulin glargine, as Lantus. However, Lantus and Toujeo are available in different strengths.

While Lantus is available at 100 units/mL, Toujeo comes in a higher concentration at 300 units/mL. Toujeo is also not dispensed in vials, unlike Lantus or Levemir.

In what dosage form and strength will Toujeo be available?
Toujeo will be available as a disposable prefilled 300 units/mL SoloStar Pen. It will be dispensed in packages of three or five pens.

How is Toujeo used?
Toujeo is to be administered subcutaneously ONCE DAILY at the same time each day.

What are the side effects of Toujeo?

The most common side effects associated with Toujeo are hypoglycemia, allergic reaction, injection site reaction, loss of body fat at injection sites, itching, rash, edema, weight gain.

Drugs featured in this story

Filed under